Cargando…

Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma

The current definition of plasma cell leukemia (PCL)— ≥ 20% circulating plasma cells (CPCs) on peripheral smear and plasma cell count ≥ 2 × 10(9)/L—may be too stringent. We reviewed outcomes of 176 multiple myeloma (MM) patients diagnosed between 1971 and 2016, and who had CPCs detectable at diagnos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ravi, Praful, Kumar, Shaji K., Roeker, Lindsey, Gonsalves, Wilson, Buadi, Francis, Lacy, Martha Q., Go, Ronald S., Dispenzieri, Angela, Kapoor, Prashant, Lust, John A., Dingli, David, Lin, Yi, Russell, Stephen J., Leung, Nelson, Gertz, Morie A., Kyle, Robert A., Bergsagel, P. Leif, Rajkumar, S. Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238010/ https://www.ncbi.nlm.nih.gov/pubmed/30442928 http://dx.doi.org/10.1038/s41408-018-0140-1

Ejemplares similares

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
por: Lakshman, Arjun, et al.
Publicado: (2018)

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
por: Rajkumar, S, et al.
Publicado: (2023)

Beta‐blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation
por: Hwa, Yi L., et al.
Publicado: (2016)

Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)
por: Pang, Li, et al.
Publicado: (2021)

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response to Therapy
por: Moustafa, Muhamad Alhaj, et al.
Publicado: (2015)

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
por: Ravi, P, et al.
Publicado: (2017)

Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation
por: Sy-Go, Janina Paula T., et al.
Publicado: (2020)

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement
por: Gonsalves, Wilson I., et al.
Publicado: (2018)

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
por: Ravi, P, et al.
Publicado: (2016)

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
por: Vaxman, I., et al.
Publicado: (2023)

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma
por: Kumar, Shaji K., et al.
Publicado: (2018)

P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma
por: Milani, Paolo, et al.
Publicado: (2016)

The Impact of Re-induction Prior to Salvage Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2019)

P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE
por: Vaxman, I., et al.
Publicado: (2022)

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
por: Kumar, Shaji K., et al.
Publicado: (2013)

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
por: Abdallah, Nadine, et al.
Publicado: (2020)

Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy
por: Siontis, B, et al.
Publicado: (2015)

Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
por: Visram, Alissa, et al.
Publicado: (2021)

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
por: Vaxman, I., et al.
Publicado: (2021)

Comparable Outcomes using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2018)

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma
por: Tschautscher, Marcella A., et al.
Publicado: (2020)

Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients
por: Visram, Alissa, et al.
Publicado: (2021)

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
por: Vu, T, et al.
Publicado: (2015)

Colon perforation in multiple myeloma patients – A complication of high‐dose steroid treatment
por: Vaxman, Iuliana, et al.
Publicado: (2020)

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
por: Sidiqi, M. Hasib, et al.
Publicado: (2018)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

P-208: Association of thrombocytopenia with disease burden, high-risk cytogenetics, and survival in newly diagnosed multiple myeloma patients
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation
por: Chakraborty, Rajshekhar, et al.
Publicado: (2017)

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma
por: Gonsalves, W I, et al.
Publicado: (2015)

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
por: Paquin, Ashley R., et al.
Publicado: (2018)

The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

Outcomes after biochemical or clinical progression in patients with multiple myeloma
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
por: Muchtar, Eli, et al.
Publicado: (2022)

Kidney Transplant Outcomes of Patients With Multiple Myeloma
por: Heybeli, Cihan, et al.
Publicado: (2022)

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma
por: Tandon, N, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_57ftklkf5focgelq10n06di8j2